Clinical trial · Observational
The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.
The Short-term Efficacy of Novel No-touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma With Cirrhosis.
NCT04513119CI-TRIAL-00046629unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Stage I | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Radiofrequency Ablation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The incidence of local tumor progression (LTP)
- timeFrame
- two-years local tumor progression-free survival
- description
- LTP was defined as the appearance of new tumor foci near 2 cm at the ablative margin after the local eradication of all tumor cells with RFA
Secondary outcomes (1)
- measure
- Tumor-free survival
- timeFrame
- two-years tumor-free survival
- description
- The tumor did not recur after treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Primary hepatocellular carcinoma with a background of cirrhosis * Single shot with diameter ≤ 3cm * The tumor did not invade portal vein, hepatic vein trunk and secondary branches * Child Pugh A/B * ICG-R15 ≤ 30% * 18-70 years old * The follow-up time reached 2 years Exclusion Criteria: * The follow-up time is less than 2 years * multiple lesions or diameter \> 3cm * Previous history of upper gastrointestinal bleeding or severe hypersplenism * Patients with extrahepatic or lymph node metastasis * Wish to receive liver transplantation and hepatectomy * The lesion is adjacent to the gallbladder, important blood vessels and bile ducts in the hilum of the liver and important organs around * severe bleeding tendency, platelet count \< 50 × 10\^9/L, or prothrombin time prolonged \> 3s * Other anti-tumor therapies were accepted before surgery
References
Publications (0)
Data not yet available
No reference posted for this study.